{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:56Z","timestamp":1792461116999,"version":"4.5.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Standard adjuvant therapy for human papillomavirus\u2013associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is radiation therapy 60 Gy with or without cisplatin delivered in 30 fractions during 6 weeks. A phase 3 randomized clinical trial demonstrated decreased toxic effects and improved patient-reported outcomes with de-escalated adjuvant radiation therapy (DART) compared with standard therapy; however, outcomes for patients treated in the clinical practice setting following trial adoption remain unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare characteristics and oncologic outcomes of patients treated with DART during clinical trials (on study) and in clinical practice settings (off study) and report progression-free survival (PFS) by risk category.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study included patients treated with DART in the MC1273 and MC1675 trials and in clinical practice after study completion at a multisite tertiary care center. Patients with surgically resectable HPV-OPSCC who underwent margin-negative resection between August 20, 2013, and March 21, 2023, and were treated with DART were included in the analysis. Those with prior head and neck cancer, pT0 or pT4 disease, unknown HPV status, metastatic disease at presentation, synchronous primary tumors, induction chemotherapy, or treatment at an outside institution were excluded. Data were analyzed from July 1, 2024, to July 18, 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n DART consisting of 30 to 36 Gy in 1.5- to 1.8-Gy fractions twice daily with docetaxel 15 mg\/m\n 2<\/jats:sup>\n on days 1 and 8.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Progression-free survival as measured via Kaplan-Meier analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 282 patients were included in the analysis: 176 (62.4%) in the on-study group and 106 (37.6%) in the off-study group (252 [89.4%] male; mean [SD] age, 59.1 [9.3] years). Both groups were predominantly male (157 [89.2%] and 95 [89.6%], respectively) and consisted mostly of never smokers (118 [67.0%] and 62 [58.5%], respectively). Pathologic features were similar between groups except for nodal stage (pN1: 155 [88.1%] on study vs 102 [96.2%] off study; pN2: 21 [11.9%] on study vs 4 [3.8%] off study;\n P<\/jats:italic>\n \u2009=\u2009.02). The median follow-up times were 5.2 years (95% CI, 5.2-5.8 years) in the on-study group and 2.2 years (95% CI, 1.9-2.4 years) in the off-study group. Two-year PFS was similar (93% [95% CI, 88%-97%] on study vs 93% [95% CI, 88%-99%] off study). For patients with pN1 and no extranodal extension (ENE), 2- and 5-year PFS were 97% (95% CI, 93%-100%) and 96% (95% CI, 92%-100%), respectively. Patients with pN1 and ENE had a 2- and 5-year PFS of 93% (95% CI, 89%-98%) and 87% (95% CI, 81%-94%), respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this retrospective cohort study of patients receiving DART on and off study, oncologic outcomes were similar between the 2 groups. Fewer patients with pN2 received DART off study, given the interim results of MC1675. Patients with pN1 and no ENE treated with DART had excellent 2- and 5-year PFS, supporting DART as a compelling treatment option in well-selected patients. An additional study that is currently underway will evaluate biomarker risk-stratified treatment of patients with pN1 and ENE receiving DART.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.12837","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:30:23Z","timestamp":1779118223000},"page":"e2612837","source":"Crossref","is-referenced-by-count":2,"title":["De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Cecelia M.","family":"Hidalgo","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron W.","family":"Bogan","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Division of Biostatistics, Mayo Clinic, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn S.","family":"Rourk","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Q.","family":"Baratz","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Eyassu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Price","sequence":"additional","affiliation":[{"name":"Division of Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir H.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Hinni","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Neben-Wittich","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda I.","family":"Garces","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"McGee","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude M.","family":"Rwigema","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish V.","family":"Chintakuntlawar","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homan","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Holtzman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Janus","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Foote","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall K.","family":"Tasche","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Van Abel","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda X.","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Routman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"zoi260386r1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260386r2","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.ijrobp.2021.07.155","article-title":"Long-term results for MC1273, a phase ii evaluation of de-escalated adjuvant radiation therapy for human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC).","volume":"111","author":"Ma","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi260386r3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311).","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi260386r4","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S1470-2045(25)00324-9","article-title":"De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial.","volume":"26","author":"Ma","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi260386r5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ijrobp.2021.09.012","article-title":"MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma.","volume":"111","author":"Ma","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi260386r6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ijrobp.2022.05.047","article-title":"Long-term toxic effects, swallow function, and quality of life on MC1273: a phase 2 study of dose de-escalation for adjuvant chemoradiation in human papillomavirus-positive oropharyngeal cancer.","volume":"114","author":"Price","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi260386r7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijrobp.2020.12.021","article-title":"Costs of definitive chemoradiation, surgery, and adjuvant radiation versus de-escalated adjuvant radiation per MC1273 in HPV+ cancer of the oropharynx.","volume":"110","author":"Waddle","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"zoi260386r8","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clon.2019.05.003","article-title":"Generalisability of common oncology clinical trial eligibility criteria in the real world.","volume":"31","author":"Karim","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5","key":"zoi260386r9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2025.02.003","article-title":"Mind the gap: the disconnect between clinical trials and real-world oncology patients.","volume":"87","author":"Taha","year":"2025","journal-title":"Eur Urol"},{"key":"zoi260386r10","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, a randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients.","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"zoi260386r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100926","article-title":"The number of radiographically positive lymph nodes further stratifies patient survival among clinical N1 patients with human papillomavirus-associated oropharyngeal cancer.","volume":"7","author":"Kowalchuk","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"7","key":"zoi260386r12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamaoto.2025.0903","article-title":"ctDNA and recurrence risk for adjuvant de-escalation in HPV-positive oropharyngeal carcinoma: a secondary analysis of the DART phase 3 randomized clinical trial.","volume":"151","author":"Routman","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"zoi260386r13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-24-2425","article-title":"Increased interaction between B cells and CD3+ T cells in nonprogressors with human papillomavirus\u2013associated oropharyngeal squamous cell carcinoma.","volume":"31","author":"Bartemes","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi260386r14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s43856-024-00604-w","article-title":"Integrative analysis of H&E and IHC identifies prognostic immune subtypes in HPV related oropharyngeal cancer.","volume":"4","author":"Nakkireddy","year":"2024","journal-title":"Commun Med (Lond)"},{"issue":"10","key":"zoi260386r15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1158\/1541-7786.MCR-21-0443","article-title":"Comprehensive viral genotyping reveals prognostic viral phylogenetic groups in HPV16-associated squamous cell carcinoma of the oropharynx.","volume":"20","author":"Schrank","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"1","key":"zoi260386r16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jval.2025.08.016","article-title":"Unlocking patient preferences: the potential of stated-preference methods in clinical decision-making.","volume":"29","author":"Ozdemir","year":"2026","journal-title":"Value Health"},{"issue":"11","key":"zoi260386r17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1200\/JCO-24-02755","article-title":"Transoral robotic surgery in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma: ASCO guideline.","volume":"43","author":"Holsinger","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849121\/hidalgo_2026_oi_260386_1778512980.22445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:30:24Z","timestamp":1779118224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.12837","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}